Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5601 in Relapsed and Refractory IgG4-related Disease
NCT07298590Phase 1Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5601 in IgG4-related disease (IgG4-RD), sponsored by Changhai Hospital. Primary endpoints: Dose-Limiting Toxicity at 48 weeks, Treatment Emergent Adverse Events at 48 weeks and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
KN5601
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07298590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298590.